Study of AZD2811 + durvalumab in ES-SCLC

Trial Identifier: D6132C00001
Sponsor: AstraZeneca
NCTID:: NCT04745689
Start Date: February 2021
Primary Completion Date: June 2022
Study Completion Date: March 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Spanish Translation
Polish Translation
Korean Translation

Trial Locations

Country Location
AU North Gosford, AU, 2250
AU Wollongong, AU, 2500
CA, NB Moncton, NB, CA, E1C 6Z8
CA, QC Montreal, QC, CA, H2X 0A9
DE Braunschweig, DE, 38114
DE Esslingen, DE, 73730
DE Hamburg, DE, 21075
DE Immenhausen, DE, 34376
DE Karlsruhe, DE, 76137
DE Luebeck, DE, 23538
DE Regensburg, DE, 93053
ES Barcelona, ES, 08003
ES Barcelona, ES, 08035
ES Madrid, ES, 28041
ES Madrid, ES, 28027
ES Madrid, ES, 28007
ES Pozuelo de Alarcón, ES, 28223
ES Sevilla, ES, 41071
ES Valencia, ES, 46010
ES Valencia, ES, 46015
IT Milano, IT, 20132
IT Orbassano, IT, 10043
IT Rome, IT, 168
IT Verona, IT, 37124
KR Cheongju-si, KR, 28644
KR Jinju-si, KR, 52727
KR Seoul, KR, 138-736
KR Seoul, KR, 03722
KR Seoul, KR, 6351
KR Seoul, KR, 06591
PL Bydgoszcz, PL, 85-796
PL Olsztyn, PL, 10-357
PL Poznan, PL, 60-693
US, GA Atlanta, GA, US, 30318
US, KY Louisville, KY, US, 40217
US, MA Boston, MA, US, 02215
US, MI Grand Rapids, MI, US, 49503
US, OH Cleveland, OH, US, 44106
US, TN Nashville, TN, US, 37203
US, TX Houston, TX, US, 77030